Updated:
Remedium Capital Partners
Remedium Capital Partners was founded by Scott Dilworth, formerly a hedge fund manager at firms including Citadel and Point72 (per public record).
Remedium Capital Partners
Remedium Capital Partners was founded by Scott Dilworth, formerly a hedge fund manager at firms including Citadel and Point72 (per public record). The firm operates as a single-family office out of New York, with a mandate that spans multiple asset classes and geographies. The strategy blends opportunistic direct investments with fund commitments, focusing on lower-middle-market companies in health care services, life sciences, industrial technology, and energy transition. Remedium also engages in real estate and private credit transactions. Notable co-investment partners have included Sterling Partners and MiddleGround Capital (per public sources). Geographically, the firm targets North America and Western Europe. Remedium appears to maintain a lean team, though exact headcount and AUM are not publicly disclosed. The firm has not publicly listed additional offices or affiliated philanthropic structures. Recent activity includes a 2024 debt investment in a specialty pharmaceutical company alongside a healthcare-focused credit manager (per SEC filings, 2024). A structural differentiator is the firm's hybrid approach — operating as a direct co-investor in sponsor-led deals while maintaining the flexibility of a single-family office, allowing for faster decisions and longer hold periods than many institutional peers.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Scott Dilworth
Founder and Managing Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Remedium Capital Partners?
Scott Dilworth is the founder and managing partner, responsible for overall investment strategy and execution. He previously worked as a portfolio manager at Citadel and Point72 (per public record).
What investment stages and deal structures does Remedium target?
Remedium focuses on direct co-investments alongside institutional sponsors, as well as fund commitments. It targets lower-middle-market companies and also engages in private credit and real estate transactions.
How does Remedium source proprietary deal flow?
Remedium relies on a network of relationships with mid-market private equity firms, credit funds, and family offices. It does not maintain a public sourcing platform or disclose a proprietary pipeline.
Does Remedium have a public track record of fund investments or direct deals?
The firm has been identified as a co-investor in private credit facilities alongside specialist healthcare credit managers, as reflected in SEC filings. No full portfolio or fund-level returns are publicly available.
Is Remedium structured as a single-family office or does it manage outside capital?
Remedium operates as a single-family office, managing the Dilworth family's capital. It does not market to third-party investors or operate a multi-family office structure.
What sectors does Remedium explicitly avoid?
The firm does not publicly disclose any exclusion lists. Based on disclosed activity, it does not appear to invest in early-stage venture, cryptocurrency, or public equities.
Where does the underlying wealth come from?
The wealth originates from Scott Dilworth's career as a hedge fund manager, including roles at Citadel and Point72 (per public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: